This is a rare genetic condition called Amylopectinosis. It affects how your body stores energy. Specifically, it causes a buildup of a type of sugar called glycogen in your muscles and liver. This buildup can lead to muscle weakness and liver problems.
Every report comes from a Lived member, sent anonymously.
Have you had Liver Transplant for Amylopectinosis?
Amylopectinosis, better known as glycogen storage disease type IV (GSD IV) or Andersen disease, is a very rare inherited condition in which the body cannot build glycogen properly. Glycogen is the form in which the body stores sugar for energy, mainly in the liver and muscles. In GSD IV, an enzyme that normally adds branches to glycogen is missing or weak, so the body makes long, poorly branched chains (called polyglucosan) instead. These abnormal deposits build up inside cells and gradually damage them. The liver and muscles are affected most, but the heart and nerves can be too. How the condition shows itself varies more than in almost any other inherited disease. The most common form begins in infancy with poor weight gain and an enlarged liver that progresses to scarring (cirrhosis). Other forms affect mainly the muscles and heart, from severe disease before or just after birth to milder weakness that starts in later childhood. Some children have liver involvement that does not progress to liver failure. An adult-onset form, called adult polyglucosan body disease (APBD), affects the nerves and typically causes bladder problems, stiffness and weakness in the legs, and numbness in the feet.
GSD IV is caused by changes (variants) in the GBE1 gene, which carries the instructions for the glycogen branching enzyme. It is inherited in an autosomal recessive pattern: a child is affected only when they receive a nonworking copy of the gene from each parent. Parents who each carry one copy usually have no symptoms. When both parents are carriers, each pregnancy has a 25% chance of an affected child, a 50% chance of a child who is a carrier, and a 25% chance of a child who neither has the condition nor carries it. In general, people whose enzyme works least tend to have the most severe forms, but the specific gene variants do not reliably predict how someone will do, and even siblings can have different ages of onset. Nothing a parent did during pregnancy causes GSD IV, and no diet or activity triggers it.
A diagnosis is often first suspected when an infant is not gaining weight and has an enlarged liver with abnormal liver blood tests, or when a child or adult has unexplained muscle weakness, a weakened heart, or, in APBD, a combination of bladder and walking problems. A liver or muscle biopsy may show the abnormal glycogen deposits. The diagnosis is confirmed by genetic testing that finds disease-causing variants in both copies of the GBE1 gene, or by measuring low branching enzyme activity in liver, muscle or skin cells. Because GSD IV is so rare and so variable, misdiagnosis and delays are common, and evaluation at a center experienced in metabolic diseases helps. Once GSD IV is confirmed, the workup looks at every system it can affect: liver blood tests, including clotting tests, an ultrasound of the liver, a heart ultrasound (echocardiogram), and assessments of muscle strength, nerves and nutrition. Once the family's gene variants are known, other relatives can have carrier testing, and testing is possible in future pregnancies.
There is no treatment that corrects the enzyme shortage. Care aims to protect the liver, heart and muscles and to support growth and development, ideally through a team that includes specialists in liver disease, heart disease, neurology, nutrition and genetics. For children whose liver disease progresses toward liver failure, a liver transplant is the only effective treatment. A new liver replaces the failing one, but it does not treat the heart, muscles or nerves, and transplant carries a high risk of complications, partly because the heart may also be affected. Because some children with early liver scarring later stabilize, specialists often weigh a period of close monitoring against moving straight to transplant. A heart transplant is sometimes considered when heart involvement is severe. Nutrition support helps children grow and prevents shortages of vitamins A, D, E and K, which a damaged liver absorbs poorly. Various diets have been tried, but there is no agreed GSD IV diet and no proof that diet slows the disease. Physical therapy and developmental support help children with weak muscles or low muscle tone. Because liver disease can impair blood clotting, clotting is checked before any surgery so that bleeding can be prevented.
The outlook depends heavily on which form a person has. Without a liver transplant, children with the classic progressive liver form usually die of liver failure by about age five. The forms that are severe from birth are usually fatal in the newborn period or early infancy. In contrast, many people with the milder liver form reach adulthood, and the childhood muscle form ranges from mild weakness to serious heart disease in young adulthood. Even when liver disease seems to settle, scarring can remain, and a small number of people have developed serious liver problems, including liver cancer, years later. For that reason, follow-up is lifelong, with regular liver blood tests, liver ultrasounds and nutritional checks. If the first heart ultrasound is normal, it is typically repeated every three months during infancy, every six months in early childhood and yearly after that. For families, daily life often involves frequent appointments and decisions about transplant made with limited data. Connecting with a metabolic genetics center and with other families affected by glycogen storage diseases can help with planning and support.
Ask for an evaluation if an infant is not gaining weight or has a swollen belly, if a child has unexplained muscle weakness or delayed motor milestones, or if an adult develops a combination of bladder problems, leg stiffness and numbness. Families with a known GBE1 variant can discuss carrier or pregnancy testing. For someone already diagnosed, contact the care team promptly about yellowing of the skin or eyes, new confusion or sleepiness, a rapidly enlarging belly, or new shortness of breath, leg swelling or trouble feeding, which can signal worsening liver or heart function. Vomiting or coughing up blood can mean bleeding from enlarged veins in the esophagus, a complication of cirrhosis, and needs emergency care by calling 911.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Amylopectinosis is like, what's helped you, or ask the community a question.